Nicoya Life
Nicoya Lifesciences develops label-free biophysical characterization instruments that enable researchers to measure protein binding, structure, stability, and kinetics across the drug discovery and development workflow. The company's product portfolio spans three categories: binding kinetics (Revo, a next-generation digital SPR platform; Alto, the world's first digital SPR system; OpenSPR; and SX20 stopped-flow),…
Funding snapshot
About
Nicoya Lifesciences develops label-free biophysical characterization instruments that enable researchers to measure protein binding, structure, stability, and kinetics across the drug discovery and development workflow. The company's product portfolio spans three categories: binding kinetics (Revo, a next-generation digital SPR platform; Alto, the world's first digital SPR system; OpenSPR; and SX20 stopped-flow), stability and structure (SUPR-DSF differential scanning fluorimetry and Chirascan circular dichroism), and structural dynamics (FastHDX, a millisecond hydrogen-deuterium exchange mass spectrometry platform). Nicoya's instruments are designed to reduce barriers to high-quality data through automated workflows, low sample consumption, and reproducible publication-quality results. The integrated portfolio supports confident decisions from discovery through development, serving discovery and optimization, mechanism of action characterization, and stability and quality applications. The company is trusted by top pharmaceutical companies and leading academic institutions worldwide. Founded in 2012 and headquartered in Kitchener, Canada, Nicoya Lifesciences has raised $35 million in a Series A round backed by the Golden Triangle Angel Network, MaRS IAF, Maple Leaf Angels, Innovation Grade Ventures, BDC Capital, University of Waterloo, and Waterloo Alumni Angels.
Business model
Nanotechnology > Nanotools > Surface Analysis Tool > Optical Microscope > Hyperspectral,
Life Sciences Platforms and Tools > Instruments > Biosensors > Surface Plasmon Resonance,
Photonics > Nanophotonics > Nanocharacterisation Techniques > Spectroscopy > Surface Plasmon Resonance,
Materials Tech > Research and Development > Microscopy > Optical Microscope > Hyperspectral
Institutional investors
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.